Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Rusconi

Showing results (161-170 of 192) with videos related to

Pageof 20
Sort By:
The Journal of Antimicrobial Chemotherapy|April 19, 2018
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trialMassimiliano Fabbiani, Roberta Gagliardini, Nicoletta Ciccarelli, et al.
AIDS (London, England)|March 17, 2023
Incident diabetes in course of antiretroviral therapyLucia Taramasso, Nicola Squillace, Elena Ricci, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2022
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized TrialLaura Waters, Lambert Assoumou, Ana González-Cordón, et al.
Pharmacological Research|May 25, 2020
30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort studyAndrea Giacomelli, Anna Lisa Ridolfo, Laura Milazzo, et al.
Elife|March 2, 2021
Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control studyChiara Fallerini, Sergio Daga, Stefania Mantovani, et al.
Sexually Transmitted Infections|April 21, 2022
Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in ItalyGiorgio Bozzi, Lavinia Fabeni, Isabella Abbate, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 19, 2023
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 TrialAbiu Sempere, Lambert Assoumou, Ana González-Cordón, et al.
Antimicrobial Resistance and Infection Control|August 29, 2022
What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centresAgnese Comelli, Camilla Genovese, Andrea Lombardi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 27, 2020
Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" StudyAndrea Gori, Andrea Antinori, Alessandra Vergori, et al.
Pharmacological Research|May 15, 2020
Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation statusSpinello Antinori, Maria Vittoria Cossu, Anna Lisa Ridolfo, et al.
Pageof 20

Showing results (161-170 of 192) with videos related to

Sort By:
Pageof 20
The Journal of Antimicrobial Chemotherapy|April 19, 2018
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trialMassimiliano Fabbiani, Roberta Gagliardini, Nicoletta Ciccarelli, et al.
AIDS (London, England)|March 17, 2023
Incident diabetes in course of antiretroviral therapyLucia Taramasso, Nicola Squillace, Elena Ricci, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2022
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized TrialLaura Waters, Lambert Assoumou, Ana González-Cordón, et al.
Pharmacological Research|May 25, 2020
30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort studyAndrea Giacomelli, Anna Lisa Ridolfo, Laura Milazzo, et al.
Elife|March 2, 2021
Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control studyChiara Fallerini, Sergio Daga, Stefania Mantovani, et al.
Sexually Transmitted Infections|April 21, 2022
Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in ItalyGiorgio Bozzi, Lavinia Fabeni, Isabella Abbate, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 19, 2023
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 TrialAbiu Sempere, Lambert Assoumou, Ana González-Cordón, et al.
Antimicrobial Resistance and Infection Control|August 29, 2022
What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centresAgnese Comelli, Camilla Genovese, Andrea Lombardi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 27, 2020
Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" StudyAndrea Gori, Andrea Antinori, Alessandra Vergori, et al.
Pharmacological Research|May 15, 2020
Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation statusSpinello Antinori, Maria Vittoria Cossu, Anna Lisa Ridolfo, et al.
Pageof 20